EUVIMEDEUVIMED entdecken
Crossref

Dual Antiplatelet Therapy after Intravenous Thrombolysis for Acute Minor Ischemic Stroke

Guangjian Zhao, Fanzhen Lin, Ziran Wang, Xiaolin Shao, Yanxue Gong, Shirui Zhang, Yansen Cui, Daiqun Yang, Hongyan Lei, Zhongrong Cheng, Liquan Wang, Dongdong Guo und 1 weitere

European Neurology · 2019 · 82 (4-6) · 93-98

DOI: 10.1159/000505241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Neurology, online erschienen am 08.01.2020. Verfasst von Guangjian Zhao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Linyi People's Hospital, Linyi, China. Die Arbeit wurde bisher 20-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To verify the efficacy and safety of dual antiplatelet therapy after intravenous thrombolysis for acute minor ischemic stroke (AMIS).

Methods

AMIS patients who received recombinant tissue plasminogen activator (rt-PA) intravenous thrombolysis from January to October 2018 were retrospectively analyzed and divided into the aspirin (ASP) and ASP + clopidogrel (ASP-CLO) groups based on the type of antiplatelet therapy to compare the rates of good clinical outcome, symptomatic intracranial hemorrhage (SICH) after thrombolysis, and mortality in 90 days.

Results

A total of 207 patients were included (group ASP, 105 patients; group ASP-CLO, 102 patients). There was no significant difference in the baseline clinical data between the 2 groups. The ­90-day modified Rankin scale scores (66.7 vs. 82.4%, p = 0.009) showed a statistically significant difference, but SICH (1.0 vs. 1.0%, p = 0.917) and 90-day mortality (1.9 vs. 1.0%, p = 0.585) showed no significant difference between the 2 groups.

Conclusions

Short-term (21 days) dual antiplatelet therapy after rt-PA intravenous thrombolysis for AMIS can improve the prognosis, reduce the risk of stroke recurrence, without increasing the risk of bleeding and mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Administration, IntravenousAgedAspirinBrain IschemiaClopidogrelDual Anti-Platelet TherapyFemaleHumansMaleMiddle AgedPlatelet Aggregation InhibitorsPrognosisRetrospective StudiesStrokeThrombolytic TherapyTissue Plasminogen ActivatorTreatment Outcome

Stichwörter der Autor:innen

Acute minor ischemic strokeDual antiplatelet therapyIntravenous thrombolysisSafety

Substanzen

Platelet Aggregation InhibitorsClopidogrelTissue Plasminogen ActivatorAspirin

Autor:innen und Institutionen

  • Department of Neurology, Linyi People's Hospital, Linyi, China.
  • General Medicine, Linyi People's Hospital, Linyi, China.
  • Diagnostics Teaching and Research Office, Shandong Medical College, Linyi, China.
  • Department of Neurology, Linyi People's Hospital, Linyi, China, cnqinghuazhang@163.com.

Zitieren

APA

Zhao, G., Lin, F., Wang, Z., Shao, X., Gong, Y., Zhang, S., Cui, Y., Yang, D., Lei, H., Cheng, Z., Wang, L., Guo, D., & Zhang, Q. (2019). Dual Antiplatelet Therapy after Intravenous Thrombolysis for Acute Minor Ischemic Stroke. European Neurology, 82(4-6), 93-98. https://doi.org/10.1159/000505241

Vancouver

Zhao G, Lin F, Wang Z, Shao X, Gong Y, Zhang S, et al. Dual Antiplatelet Therapy after Intravenous Thrombolysis for Acute Minor Ischemic Stroke. European Neurology. 2019;82(4-6):93-98. doi:10.1159/000505241

BibTeX
@article{Zhao2019,
  author = {Zhao, Guangjian and Lin, Fanzhen and Wang, Ziran and Shao, Xiaolin and Gong, Yanxue and Zhang, Shirui and Cui, Yansen and Yang, Daiqun and Lei, Hongyan and Cheng, Zhongrong and Wang, Liquan and Guo, Dongdong and Zhang, Qinghua},
  title = {Dual Antiplatelet Therapy after Intravenous Thrombolysis for Acute Minor Ischemic Stroke},
  journal = {European Neurology},
  year = {2019},
  volume = {82},
  number = {4-6},
  pages = {93--98},
  doi = {10.1159/000505241}
}
Kostenlos starten →